

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM727829

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ENTITY CONVERSION		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Anika Therapeutics, Inc.		06/06/2018	Corporation: MASSACHUSETTS
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Anika Therapeutics, Inc.		
<b>Street Address:</b>	32 Wiggins Avenue		
<b>City:</b>	Bedford		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	01730		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 10</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	90320746	RESTORE ACTIVE LIVING	
<b>Registration Number:</b>	4143417	ANIKA	
<b>Registration Number:</b>	3938038	ANIKA THERAPEUTICS	
<b>Registration Number:</b>	3937877	A ANIKA THERAPEUTICS	
<b>Registration Number:</b>	4147326	ANIKAVISC	
<b>Registration Number:</b>	4593175	CINGAL	
<b>Registration Number:</b>	1023067	HYVISC	
<b>Registration Number:</b>	4495140	MONOVISC	
<b>Registration Number:</b>	1834288	ORTHOVISC	
<b>Registration Number:</b>	6015103	TACTOSET	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	9495676710		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	617-880-1877		
<b>Email:</b>	cvicino@orrick.com		
<b>Correspondent Name:</b>	Robert M. O'Connell Jr.		
<b>Address Line 1:</b>	Orrick, Herrington & Sutcliffe LLP		
<b>Address Line 2:</b>	2050 Main Street, Suite 1100		

CH \$265.00 90320746

<b>Address Line 4:</b>	Irvine, CALIFORNIA 92614
<b>ATTORNEY DOCKET NUMBER:</b>	44703.6000
<b>NAME OF SUBMITTER:</b>	Robert M. O'Connell Jr.
<b>SIGNATURE:</b>	/Robert M. O'Connell, Jr./
<b>DATE SIGNED:</b>	05/13/2022
<b>Total Attachments: 1</b> source=Anika - Certificate of Conversion#page1.tif	

**CERTIFICATE OF CONVERSION**  
**FROM A NON-DELAWARE CORPORATION TO A DELAWARE CORPORATION**  
*Pursuant to Section 265 of the Delaware General Corporation Law*

This Certificate of Conversion from a Non-Delaware Corporation to a Delaware Corporation (this “*Certificate*”) is being filed with the Secretary of State of the State of Delaware in connection with the conversion of Anika Therapeutics, Inc., a Massachusetts corporation (the “*Non-Delaware Corporation*”) into Anika Therapeutics, Inc., a Delaware corporation (the “*Corporation*”).

- (1) The jurisdiction where the Non-Delaware Corporation first formed is **Massachusetts**.
- (2) The jurisdiction of the Non-Delaware Corporation as of immediately prior to the filing of this Certificate is **Massachusetts**.
- (3) The date on which the Non-Delaware Corporation first formed is **February 28, 1992**.
- (4) The name and type of entity of the Non-Delaware Corporation immediately prior to the filing of this Certificate is **Anika Therapeutics, Inc.**, a Massachusetts corporation.
- (5) The name of the Corporation as set forth in its certificate of incorporation is **Anika Therapeutics, Inc.**
- (6) This Certificate shall become effective as of 5:00 pm, Eastern daylight saving time, on June 6, 2018.

IN WITNESS WHEREOF, the undersigned, being duly authorized to sign on behalf of the converting Non-Delaware Corporation, has executed this Certificate as of June 6, 2018.

By:           /s/ Joseph G. Darling            
Chief Executive Officer and President